PHOX is virtually not accessible.9 This drawback has serious
consequence in asymmetric catalysis since it limits access
to one enantiomeric series for any given reaction using the
t-Bu-PHOX ligand. In this context, a readily accessible
substitute for t-Bu-PHOX that would be available in both
enantiomeric series at reasonable cost would be highly
valuable.10
the i-Pr where the two methyl groups pointed toward the
reaction center (i.e., enolate fragment) such that the i-Pr
mimicked a tert-butyl group.11a
On the basis of these results, we envisioned that the
incorporation of a gem-dimethyl group at C-4 of i-Pr-PHOX
(2) could result in a practical replacement for t-Bu-PHOX
(1). These new ligands would not only have a major
economic advantage over t-Bu-PHOX since the cost of the
starting amino acids, (S)- or (R)-valine (8), is much lower
than the corresponding tert-leucines (6) but also allow easy
access to both enantiomers.
It has been shown by Davies11 that the incorporation
of a gem-dimethyl group at C-5 of a 4-iso-propyloxazo-
lidinone (Evans’ auxiliary) resulted in a chiral auxiliary
that behaved similarly to a 4-tert-butyl-propyloxazolidi-
none in terms of stereoinduction in a wide range of
transformations. It was also demonstrated that steric
interaction between the gem-dimethyl group at C-5 and
the iso-propyl group at C-4 resulted in a conformation of
Herein, we describe a new and readily available member
of the PHOX family,12 5,5-(dimethyl)-i-Pr-PHOX (7) (Figure
2), which has a parallel reactivity to (S)-t-Bu-PHOX with
(4) For recent examples of the use of (S)-t-Bu-PHOX in total synthesis,
see: (a) Coe, J. W. Org. Lett. 2000, 2, 4205–4208. (b) Bian, J.; Van
Wingarden, M.; Ready, J. M. J. Am. Chem. Soc. 2006, 128, 7428–7429.
(c) Behenna, D. C.; Stockdill, J. L.; Stoltz, B. N. Angew. Chem., Int. Ed.
2007, 46, 4077–4080. (d) Enquist, J. A., Jr.; Stoltz, B. M. Nature 2008,
453, 1228–1231. (e) Dounay, A. M.; Humphreys, P. G.; Overman, L. E.;
Wrobleski, A. D. J. Am. Chem. Soc. 2008, 130, 5368–5377.
(5) Available from Sigma-Aldrich Co.
(6) Peer, M.; de Jong, J. C.; Jiefer, M.; Langer, T.; Rieck, H.; Schell,
H.; Sennhenn, P.; Sprinz, J.; Steinhagen, H.; Wiese, B.; Helmchen, G.
Tetrahedron 1996, 52, 7547–7583.
(7) The price per gram (in American dollars) was calculated using the
largest amount available from Sigma-Aldrich Co. (March 2009).
(8) Bommarius, A. S.; Schwarm, M.; Stingl, K.; Kottenhahn, M.;
Huthmacher, K.; Drauz, K. Tetrahedron: Asymmetry 1995, 6, 2851–2888.
(9) According to a recent SciFinder Scholar search (March 2009), only
5 examples of the use of (R)-t-Bu-PHOX had been reported. See: (a) Juhl,
K.; Hazell, R. G.; Jørgensen, K. A. J. Chem. Soc., Perkin Trans. 1 1999,
2293–2297. (b) Fang, X.; Johannsen, M.; Yao, S.; Gathergood, N.; Hazell,
R. G.; Jørgensen, K. A. J. Org. Chem. 1999, 64, 4844–4849. (c) Marinescu,
S. C.; Nishimata, T.; Mohr, J. T.; Stoltz, B. M. Org. Lett. 2008, 10, 1039–
1042. (d) Levine, S. R.; Krout, M. R.; Stoltz, B. M. Org. Lett. 2009, 11,
289–292. (e) Petrova, K. V.; Mohr, J. T.; Stoltz, B. M. Org. Lett. 2009, 11,
293–295.
Figure 2. New ligands 5,5-(dimethyl)-i-Pr-PHOX and their syn-
thetic precursor.
(10) These issues have been partly addressed before and resulted in the
design of (S)-5 (Figure 1).6 However, to date, the use of this ligand in
asymmetric catalysis remains scarce. See: (a) Langer, T.; Joerg, J.;
Helmchen, G. Tetrahedron: Asymmetry 1996, 7, 1599–1602. (b) Wiese,
B.; Helmchen, G. Tetrahedron Lett. 1998, 39, 5727–5730.
(11) (a) Bull, S. D.; Davies, S. G.; Key, M.-S.; Nicholson, R. L.; Savory,
E. D. Chem. Commun. 2000, 1721–1722. (b) Bull, S. D.; Davies, S. G.;
Garner, A. C.; Kruchinin, D.; Key, M.-S.; Roberts, P. M.; Savory, E. D.;
Smith, A. D.; Thomson, J. E. Org. Biomol. Chem. 2006, 4, 2945–2964.
(12) Pfaltz has recently reported a few related 5,5-(disubstituted)-i-Pr-
PHOX (not including (S)- or (R)-7) that were used in a different context,
i.e., [3 + 2] cycloadditions of azomethine ylides with moderate to excellent
results). See: Stohler, R.; Wahl, F.; Pfatlz, A. Synthesis 2005, 1431–1436.
(13) Gibson, S. E.; Mainolfi, N.; Kalindjian, S. B.; Wright, P. T.; White,
A. J. P. Chem.sEur. J. 2005, 69–80.
the key advantage of being easily accessible as both
enantiomers. The synthesis of these ligands and their
application in two enantioselective Pd-catalyzed transforma-
tions will also be demonstrated.
The desired ligand can be accessed by two different routes
from a common intermediate (S)-913 (Scheme 1). The
synthesis of the latter starts from (S)-valine ((S)-8) that was
first transformed into (S)-valine methyl ester hydrochloride
salt using a known procedure.14,15 The ester was then
converted into the previously reported amino alcohol (S)-9
in a three-step process involving protection of the amine,
methyl Grignard addition followed by deprotection of the
Boc group under acidic conditions.13 From (S)-9, the route
parallels the original sequence to access (S)-t-Bu-PHOX.6
In this case, amide formation with 2-fluorobenzoyl chloride
followed by cyclization under acidic conditions16 gave (S)-
10. The latter was converted to the desired ligand (S)-7 via
a SNAr reaction using KPPh2. Although this sequence
provided easy access to (S)-7, the intrinsic limitation of the
last step, the anionic displacement, where either electron-
rich phosphine anions or electron-rich aryl fluorides cannot
be used, puts unwanted boundaries on the eventual fine-
tuning of the electronic properties of the ligand for specific
reactions. To circumvent this potential limitation, a second
route was investigated taking profit of a recently published
(14) Bowman, N. J.; Hay, M. P.; Love, S. G.; Easton, C. J. J. Chem.
Soc., Perkin Trans. 1 1998, 259–264.
(15) (S)- and (R)-valine methyl ester hydrochloride are also commercially
available.
(16) (a) Denmark, S. E.; Stavenger, R. A.; Faucher, A.-M.; Edwards,
J. P. J. Org. Chem. 1997, 62, 3375–3389. (b) Ginotra, S. K.; Singh, V. K.
Tetrahedron 2006, 62, 3573–3581.
(17) (a) Tani, K.; Behenna, D. C.; McFadden, R. M.; Stoltz, B. M. Org.
Lett. 2007, 9, 2529–2531. (b) Krout, M. R.; Mohr, J. T.; Stoltz, B. M. Org.
Synth. 2009, 86, 181–193.
(18) Gelman, D.; Jiang, L.; Buchwald, S. L. Org. Lett. 2003, 5, 2315–
2318.
(19) For reviews on the asymmetric allylic alkylation reaction, see: (a)
Paquin, J.-F.; Lautens, M. In ComprehensiVe Asymmetric Catalysis,
supplement #2; Jacobsen, E. N., Pfaltz, A., Yamamoto, H., Eds.; Springer-
Verlag: Berlin, 2004; pp 73-95, and references therein. (b) Pfaltz, A.;
Lautens, M. In ComprehensiVe Asymmetric Catalysis; Jacobsen, E. N.,
Pfaltz, A., Yamamoto, H., Eds.; Springer: New York, 1999; Vol. 2, pp
833-884, and references therein.
(20) Ligand (R)-7 was prepared using “Stoltz’s approach” in Scheme
1. See the Supporting Information for details.
2202
Org. Lett., Vol. 11, No. 10, 2009